Concepedia

Author

Christine Farenc

Université de Montpellier

Also Known As

C Farenc, C. Farenc, Christine Farenc

21

Publications

348

Citations

10

H-Index

28

Concepts

All Affiliations

Université de MontpellierSanofi (France)Bristol-Myers Squibb (United States)Laboratoire COBRACentre Hospitalier Universitaire de Nîmes
CF

About

Christine Farenc is an author at Université de Montpellier specializing in medicine, pharmacology, and chromatography.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

201

2

Biochemistry

2

2

45

3

Engineering

1

1

29

4

Health Sciences

1

1

16

5

Immunology

1

1

107

Christine Farenc

×

9

Publications

327

Citations

9

H-Index

YearCitations

Prodrugs of bisthiazolium salts are orally potent antimalarials

Henri Vial, Sharon Wein, Christine Farenc,

Proceedings of the National Academy of Sciences

2004

107

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

Tabassome Simon, Deepak L. Bhatt, L. Bergougnan,

Clinical Pharmacology & Therapeutics

2011

89

Pk-fit: A Pharmacokinetic/Pharmacodynamic and Statistical Data Analysis Software

Christine Farenc, Jean-Rock Fabreguette, Françoise Bressolle

Computers and Biomedical Research

2000

31

Quantitative determination of rocuronium in human plasma by liquid chromatography–electrospray ionization mass spectrometry

Christine Farenc, Christine Enjalbal, P. Sánchez,

Journal of Chromatography A

2001

29

High-performance liquid chromatographic method for the determination of atracurium and laudanosine in human plasma

Christine Farenc, Michel Audran, J.-Y. Lefrant,

Journal of Chromatography B Biomedical Sciences and Applications

1999

18

Clopidogrel Pharmacodynamics and Pharmacokinetics in the Fed and Fasted State: A Randomized Crossover Study of Healthy Men

Fabrice Hurbin, Xavier Boulenc, Nikki Daskalakis,

The Journal of Clinical Pharmacology

2011

16

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

P Clot, Christine Farenc, Benjamin T. Suratt,

Respiratory Research

2024

15

Pharmacokinetic‐Pharmacodynamic Modeling of Atracurium in Intensive Care Patients

Christine Farenc, Jean‐Yves Lefrant, Michel Audran,

The Journal of Clinical Pharmacology

2001

11

Quantification of Antimalarial Bisthiazolium Compounds and Their Neutral Bioprecursors in Plasma by Liquid Chromatography-Electrospray Mass Spectrometry

Olivier Nicolas, Christine Farenc, Michèle Calas,

Clinical Chemistry

2005

11

Page 1